US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cartesian Therapeutics

11.21

-0.1600-1.41%

Post-market: 11.210.00000.00%16:57 EDT

Volume:52.38K

Turnover:586.89K

Market Cap:290.95M

PE:-6.48

High:11.53

Open:11.50

Low:10.95

Close:11.37

Loading ...

Overview Company News Filings

Cartesian Therapeutics Announces New Employment Inducement Grant

Cartesian Therapeutics Inc expected to post a loss of 80 cents a share - Earnings Preview

Innovative mRNA-Based CAR-T Therapy Positions Cartesian Therapeutics for Market Leadership

Yale University Exits Cartesian Therapeutics Inc, Impacting Portfolio by -66.5%

Promising Developments and Strategic Expansion Bolster Buy Rating for Cartesian Therapeutics

Cartesian Therapeutics Says US FDA Agrees to Phase 3 Myasthenia Gravis Trial Design

MT Newswires Live

Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham

Positive Buy Rating for Cartesian Therapeutics Amid Encouraging Developments in Descartes-08 Trials

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 Aurora Trial of Descartes-08 in Myasthenia Gravis

THOMSON REUTERS

Promising Developments and Strategic Milestones Drive Buy Rating for Cartesian Therapeutics

Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham

Buy Rating for Cartesian Therapeutics Driven by Promising Clinical Pipeline and Financial Stability

BRIEF-Cartesian Therapeutics Highlights Progress And 2025 Strategic Priorities

Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of Mrna Cell Therapies for Autoimmune Diseases

THOMSON REUTERS

Cartesian Therapeutics Inc - Phase 3 Aurora Trial of Descartes-08 to Commence in 1H25

THOMSON REUTERS

Cartesian Therapeutics Inc - Cash Resources Expected to Support Operations Into Mid-2027

THOMSON REUTERS

Cartesian Therapeutics Inc - Phase 2 Sle Trial of Descartes-08 Ongoing, Data Readout Expected 2H25

THOMSON REUTERS

Intra-Cellular (ITCI) Surges 14.9%: Is This an Indication of Further Gains?

Cartesian Therapeutics announces employment inducement grants

Cartesian Therapeutics (RNAC) Has a New Rating from BTIG

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/RNAC/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RNAC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNAC\",,,,,undefined,":{"symbol":"RNAC","market":"US","secType":"STK","nameCN":"Cartesian Therapeutics","latestPrice":11.21,"timestamp":1751562000000,"preClose":11.37,"halted":0,"volume":52381,"hourTrading":{"tag":"盘后","latestPrice":11.21,"preClose":11.21,"latestTime":"16:57 EDT","volume":202,"amount":2261.12,"timestamp":1751576265467},"delay":0,"floatShares":9342592,"shares":25954291,"eps":-1.730257,"marketStatus":"Market Closed","change":-0.16,"latestTime":"07-03 13:00:00 EDT","open":11.5,"high":11.525,"low":10.95,"amount":586894.219254,"amplitude":0.050572,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.730257,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751875200000},"marketStatusCode":7,"adr":0,"listingDate":1466568000000,"exchange":"NASDAQ","adjPreClose":11.37,"postHourTrading":{"tag":"盘后","latestPrice":11.21,"preClose":11.21,"latestTime":"16:57 EDT","volume":202,"amount":2261.12,"timestamp":1751576265467},"volumeRatio":0.8735328550415753,"impliedVol":0.5626,"impliedVolPercentile":0.3889},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RNAC\",,,,,undefined,":{"symbol":"RNAC","floatShares":9342592,"roa":"-7.55%","roe":"-7029.26%","lyrEps":-4.481379,"volumeRatio":0.8735328550415753,"shares":25954291,"dividePrice":0,"high":11.525,"amplitude":0.050572,"preClose":11.37,"low":10.95,"week52Low":8.46,"pbRate":"-13.35","psRate":"8.51","week52High":26.5,"institutionHeld":0,"latestPrice":11.21,"eps":-1.730257,"divideRate":0,"volume":52381,"delay":0,"ttmEps":-1.730257,"open":11.5,"prevYearClose":17.91,"prevWeekClose":10.68,"prevMonthClose":10.39,"prevQuarterClose":10.39,"fiveDayClose":11.46,"twentyDayClose":9.54,"sixtyDayClose":10.11},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RNAC\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517156019","title":"Cartesian Therapeutics Announces New Employment Inducement Grant","url":"https://stock-news.laohu8.com/highlight/detail?id=2517156019","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517156019?lang=en_us&edition=fundamental","pubTime":"2025-03-06 20:05","pubTimestamp":1741262700,"startTime":"0","endTime":"0","summary":"FREDERICK, Md., March  06, 2025  (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatmen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/06/3038073/0/en/Cartesian-Therapeutics-Announces-New-Employment-Inducement-Grant.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2516866636","title":"Cartesian Therapeutics Inc  expected to post a loss of 80 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2516866636","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516866636?lang=en_us&edition=fundamental","pubTime":"2025-03-03 21:32","pubTimestamp":1741008764,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics Inc  expected to post a loss of80cents a share - Earnings Preview Cartesian Therapeutics Inc RNAC.OQ RNAC.O is expected to show a fall in quarterly revenue when it reports  resu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nL5N3PM11T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC"],"gpt_icon":0},{"id":"2514876826","title":"Innovative mRNA-Based CAR-T Therapy Positions Cartesian Therapeutics for Market Leadership","url":"https://stock-news.laohu8.com/highlight/detail?id=2514876826","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514876826?lang=en_us&edition=fundamental","pubTime":"2025-02-27 17:35","pubTimestamp":1740648959,"startTime":"0","endTime":"0","summary":"Thomas Smith, an analyst from Leerink Partners, maintained the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/innovative-mrna-based-car-t-therapy-positions-cartesian-therapeutics-for-market-leadership?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/innovative-mrna-based-car-t-therapy-positions-cartesian-therapeutics-for-market-leadership?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CAR","BK4022","RNAC","BK4230","BK4139"],"gpt_icon":0},{"id":"2511869750","title":"Yale University Exits Cartesian Therapeutics Inc, Impacting Portfolio by -66.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511869750","media":"GuruFocus","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511869750?lang=en_us&edition=fundamental","pubTime":"2025-02-15 00:03","pubTimestamp":1739549003,"startTime":"0","endTime":"0","summary":"Insight into Yale University (Trades, Portfolio)'s Strategic Investment Moves Yale University (Trades, Portfolio) recently submitted its 13F filing for the fourth quarter of 2024, offering a glimpse i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gurufocus.com/news/2698916/yale-university-exits-cartesian-therapeutics-inc-impacting-portfolio-by-665","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"gurufocus_highlight","symbols":["BK4139","BK4588","ITOT","BK4585","RNAC","BK4550"],"gpt_icon":0},{"id":"2507150995","title":"Promising Developments and Strategic Expansion Bolster Buy Rating for Cartesian Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2507150995","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507150995?lang=en_us&edition=fundamental","pubTime":"2025-01-29 14:16","pubTimestamp":1738131363,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Thomas Smith has reiterated their bullish stance on RNAC stock, giving a Buy rating yesterday. Thomas Smith’s rating is ba...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-developments-and-strategic-expansion-bolster-buy-rating-for-cartesian-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-developments-and-strategic-expansion-bolster-buy-rating-for-cartesian-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC"],"gpt_icon":0},{"id":"2506305691","title":"Cartesian Therapeutics Says US FDA Agrees to Phase 3 Myasthenia Gravis Trial Design","url":"https://stock-news.laohu8.com/highlight/detail?id=2506305691","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506305691?lang=en_us&edition=fundamental","pubTime":"2025-01-27 23:01","pubTimestamp":1737990086,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics  said Monday the US Food and Drug Administration has agreed to the design of its phase 3 AURORA trial for Descartes-08, its mRNA cell therapy for myasthenia gravis, a chronic autoimmune disorder that causes muscle weakness.The company said the randomized trial, expected to begin in H1, will compare Descartes-08 to a placebo in about 100 participants with acetylcholine receptor autoantibody-positive myasthenia gravis.The primary endpoint will measure the percentage of patients with a three-point or greater improvement in myasthenia gravis activities of daily living scores after four months, Cartesian added.Shares of the company were up 2.9% in recent Monday trading.Price: 19.76, Change: +0.56, Percent Change: +2.89","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2506370866","title":"Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2506370866","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506370866?lang=en_us&edition=fundamental","pubTime":"2025-01-27 21:31","pubTimestamp":1737984660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RNAC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 27, 2025 08:31 ET (13:31 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC"],"gpt_icon":0},{"id":"2506747953","title":"Positive Buy Rating for Cartesian Therapeutics Amid Encouraging Developments in Descartes-08 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2506747953","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506747953?lang=en_us&edition=fundamental","pubTime":"2025-01-27 21:15","pubTimestamp":1737983715,"startTime":"0","endTime":"0","summary":"In a report released today, Gil Blum from Needham maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report), with a price target o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/positive-buy-rating-for-cartesian-therapeutics-amid-encouraging-developments-in-descartes-08-trials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/positive-buy-rating-for-cartesian-therapeutics-amid-encouraging-developments-in-descartes-08-trials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DSGX","RNAC"],"gpt_icon":0},{"id":"2506751713","title":"Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 Aurora Trial of Descartes-08 in Myasthenia Gravis","url":"https://stock-news.laohu8.com/highlight/detail?id=2506751713","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506751713?lang=en_us&edition=fundamental","pubTime":"2025-01-27 20:00","pubTimestamp":1737979202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250127:nTUA8DYN4M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2503667312","title":"Promising Developments and Strategic Milestones Drive Buy Rating for Cartesian Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2503667312","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503667312?lang=en_us&edition=fundamental","pubTime":"2025-01-15 15:13","pubTimestamp":1736925228,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Thomas Smith has reiterated their bullish stance on RNAC stock, giving a Buy rating on January 13. Thomas Smith has given ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-developments-and-strategic-milestones-drive-buy-rating-for-cartesian-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-developments-and-strategic-milestones-drive-buy-rating-for-cartesian-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC"],"gpt_icon":0},{"id":"2503876205","title":"Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2503876205","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503876205?lang=en_us&edition=fundamental","pubTime":"2025-01-14 00:29","pubTimestamp":1736785740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RNAC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2025 11:29 ET (16:29 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC"],"gpt_icon":0},{"id":"2503582663","title":"Buy Rating for Cartesian Therapeutics Driven by Promising Clinical Pipeline and Financial Stability","url":"https://stock-news.laohu8.com/highlight/detail?id=2503582663","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503582663?lang=en_us&edition=fundamental","pubTime":"2025-01-14 00:15","pubTimestamp":1736784939,"startTime":"0","endTime":"0","summary":"Needham analyst Gil Blum maintained a Buy rating on Cartesian Therapeutics (RNAC – Research Report) today and set a price target of $41.00. Gil Blu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-for-cartesian-therapeutics-driven-by-promising-clinical-pipeline-and-financial-stability?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-for-cartesian-therapeutics-driven-by-promising-clinical-pipeline-and-financial-stability?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC"],"gpt_icon":0},{"id":"2503630424","title":"BRIEF-Cartesian Therapeutics Highlights Progress And 2025 Strategic Priorities","url":"https://stock-news.laohu8.com/highlight/detail?id=2503630424","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503630424?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:39","pubTimestamp":1736775550,"startTime":"0","endTime":"0","summary":"Jan 13  - Cartesian Therapeutics Inc   :   * CARTESIAN THERAPEUTICS HIGHLIGHTS PROGRESS AND 2025 STRATEGIC PRIORITIES ACROSS PIPELINE OF MRNA CELL THERAPIES FOR AUTOIMMUNE DISEASES   * CASH RESOURCES EXPECTED TO SUPPORT OPERATIONS INTO MID-2027   * PHASE 3 AURORA TRIAL OF DESCARTES-08 TO COMMENCE IN 1H25   * PHASE 2 SLE TRIAL OF DESCARTES-08 ONGOING, DATA READOUT EXPECTED 2H25Source text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","LU2065732104.USD","RNAC","BK4139","PRGS"],"gpt_icon":0},{"id":"2503970308","title":"Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of Mrna Cell Therapies for Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2503970308","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503970308?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:00","pubTimestamp":1736769601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nTUANDMGZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2503308458","title":"Cartesian Therapeutics Inc - Phase 3 Aurora Trial of Descartes-08 to Commence in 1H25","url":"https://stock-news.laohu8.com/highlight/detail?id=2503308458","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503308458?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:00","pubTimestamp":1736769601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nTUANDMGZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2503120308","title":"Cartesian Therapeutics Inc - Cash Resources Expected to Support Operations Into Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2503120308","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503120308?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:00","pubTimestamp":1736769601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nTUANDMGZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNAC","BK4139"],"gpt_icon":0},{"id":"2503081743","title":"Cartesian Therapeutics Inc - Phase 2 Sle Trial of Descartes-08 Ongoing, Data Readout Expected 2H25","url":"https://stock-news.laohu8.com/highlight/detail?id=2503081743","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503081743?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:00","pubTimestamp":1736769601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250113:nTUANDMGZ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2503306324","title":"Intra-Cellular (ITCI) Surges 14.9%: Is This an Indication of Further Gains?","url":"https://stock-news.laohu8.com/highlight/detail?id=2503306324","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503306324?lang=en_us&edition=fundamental","pubTime":"2025-01-13 18:34","pubTimestamp":1736764440,"startTime":"0","endTime":"0","summary":"Intra-Cellular Therapies  shares soared 14.9% in the last trading session to close at $94.87. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 1% loss over the past four weeks.The sudden soaring of the stock price was observed after ITCI announced that it has entered into a settlement agreement with Sandozregarding the Caplyta  patent litigation.The settlement agreement resolves the patent litigation brought by Intra-Cellular on Sandoz for submitting an abbreviated new drug application to the FDA seeking marketing approval for a generic version ofCaplyta in the United States before applicable patents expire.The settlement agreement allows Sandoz to start selling generic versions of Caplyta on July 1, 2040, or earlier under specific conditions. The stock price rally has also likely been fueled by a Bloomberg article which claims that J&J is in talks to buy ITCI for $10 billion.Cartesian Therapeutics, Inc.  : F","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/intra-cellular-itci-surges-14-103400066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0889565916.HKD","ITCI","LU0106261612.USD","LU0320765992.SGD","BK4007","RNAC","LU0053671581.USD","LU0012050646.USD","LU0109394709.USD","BK4139"],"gpt_icon":0},{"id":"2501020838","title":"Cartesian Therapeutics announces employment inducement grants","url":"https://stock-news.laohu8.com/highlight/detail?id=2501020838","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501020838?lang=en_us&edition=fundamental","pubTime":"2025-01-07 20:10","pubTimestamp":1736251827,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics (RNAC) announced the granting of inducement awards to three new employees. On January 2, 2025, the Company issued to these e...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-announces-employment-inducement-grants-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cartesian-therapeutics-announces-employment-inducement-grants-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","RNAC"],"gpt_icon":0},{"id":"2495503939","title":"Cartesian Therapeutics (RNAC) Has a New Rating from BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2495503939","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495503939?lang=en_us&edition=fundamental","pubTime":"2024-12-31 05:15","pubTimestamp":1735593339,"startTime":"0","endTime":"0","summary":"Cartesian Therapeutics (RNAC – Research Report) received a Buy rating and a $42.00 price target from BTIG analyst Julian Harrison today. The compan...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cartesian-therapeutics-rnac-has-a-new-rating-from-btig?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cartesian-therapeutics-rnac-has-a-new-rating-from-btig?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNAC"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":62,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RNAC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-08","symbol":"RNAC","fiscalQuarterEnding":"2025/03","expectedEps":-0.61,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-03-13","symbol":"RNAC","fiscalQuarterEnding":"2024/12","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741838400000,"reportTimeType":"pre","actualEps":-2.4},{"market":"US","date":"2024-11-07","symbol":"RNAC","fiscalQuarterEnding":"2024/09","expectedEps":-0.78,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.69},{"market":"US","date":"2024-08-08","symbol":"RNAC","fiscalQuarterEnding":"2024/06","expectedEps":-0.81,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723089600000,"reportTimeType":"pre","actualEps":0.54},{"market":"US","date":"2024-05-08","symbol":"RNAC","fiscalQuarterEnding":"2024/03","expectedEps":-0.81,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-1.97}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RNAC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RNAC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":8,"updateTime":1734667200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/RNAC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"RNAC","date":"2025-07-03","current":-7.59456,"percent":0.068657,"low":-14.109752,"twenty":-4.979046,"median":-2.003247,"eighty":-1.47767,"high":-0.322359,"avg":-3.292099,"sd":3.07879,"marketCap":290947602},"quantilePoints":[{"date":"2024-02-09","current":-12.195228,"twenty":-12.293822,"median":-12.139657,"eighty":-11.530164,"marketCap":110159496},{"date":"2024-02-16","current":-13.543282,"twenty":-12.82193,"median":-12.371802,"eighty":-12.018117,"marketCap":122336468},{"date":"2024-02-23","current":-12.9069,"twenty":-13.170416,"median":-12.72226,"eighty":-12.169773,"marketCap":116588031},{"date":"2024-03-01","current":-13.113052,"twenty":-13.187625,"median":-12.9069,"eighty":-12.193077,"marketCap":118450201},{"date":"2024-03-08","current":-0.474472,"twenty":-13.096919,"median":-12.72226,"eighty":-12.104521,"marketCap":104246325},{"date":"2024-03-15","current":-0.394571,"twenty":-13.085087,"median":-12.369113,"eighty":-0.499332,"marketCap":86691095},{"date":"2024-03-22","current":-0.518772,"twenty":-13.077916,"median":-12.18985,"eighty":-0.473381,"marketCap":113979437},{"date":"2024-03-28","current":-0.486782,"twenty":-13.018401,"median":-12.095738,"eighty":-0.472836,"marketCap":106950867},{"date":"2024-04-05","current":-0.371573,"twenty":-12.924109,"median":-11.522994,"eighty":-0.462369,"marketCap":81638284},{"date":"2024-04-12","current":-1.459867,"twenty":-12.9069,"median":-1.226402,"eighty":-0.444134,"marketCap":320747357},{"date":"2024-04-19","current":-1.398365,"twenty":-12.846668,"median":-1.459867,"eighty":-0.462369,"marketCap":307234719},{"date":"2024-04-26","current":-1.691309,"twenty":-12.729072,"median":-1.487381,"eighty":-0.467868,"marketCap":371597548},{"date":"2024-05-03","current":-1.978779,"twenty":-12.63227,"median":-1.536745,"eighty":-0.471303,"marketCap":434757574},{"date":"2024-05-10","current":-1.526348,"twenty":-12.47667,"median":-1.594687,"eighty":-0.472836,"marketCap":389021718},{"date":"2024-05-17","current":-1.839158,"twenty":-12.299559,"median":-1.62026,"eighty":-0.47633,"marketCap":468748036},{"date":"2024-05-24","current":-1.777713,"twenty":-12.193077,"median":-1.671483,"eighty":-0.482182,"marketCap":453087509},{"date":"2024-05-31","current":-2.195259,"twenty":-12.18985,"median":-1.697348,"eighty":-0.489671,"marketCap":559507906},{"date":"2024-06-07","current":-2.422885,"twenty":-12.179811,"median":-1.717665,"eighty":-0.504164,"marketCap":617523039},{"date":"2024-06-14","current":-2.045138,"twenty":-12.139657,"median":-1.777713,"eighty":-0.515905,"marketCap":521246392},{"date":"2024-06-21","current":-1.598266,"twenty":-12.069386,"median":-1.728138,"eighty":-0.518199,"marketCap":407351653},{"date":"2024-06-28","current":-1.991374,"twenty":-11.947846,"median":-1.777713,"eighty":-0.520305,"marketCap":507543431},{"date":"2024-07-05","current":-1.23169,"twenty":-11.531957,"median":-1.728138,"eighty":-0.526438,"marketCap":313922113},{"date":"2024-07-12","current":-1.241477,"twenty":-11.522994,"median":-1.709478,"eighty":-0.530124,"marketCap":316416386},{"date":"2024-07-15","current":-1.240079,"twenty":-9.729226,"median":-1.703386,"eighty":-0.53751,"marketCap":316060062},{"date":"2024-08-02","current":-1.081399,"twenty":-7.935458,"median":-1.699966,"eighty":-0.544895,"marketCap":275617201},{"date":"2024-08-09","current":-1.198323,"twenty":-2.548847,"median":-1.676743,"eighty":-0.772791,"marketCap":275192581},{"date":"2024-08-16","current":-1.345437,"twenty":-2.529995,"median":-1.625846,"eighty":-1.101689,"marketCap":308976908},{"date":"2024-08-23","current":-1.244878,"twenty":-2.507232,"median":-1.598266,"eighty":-1.148418,"marketCap":285883824},{"date":"2024-08-30","current":-1.388267,"twenty":-2.46827,"median":-1.531547,"eighty":-1.172903,"marketCap":318812851},{"date":"2024-09-06","current":-1.307262,"twenty":-2.424002,"median":-1.519153,"eighty":-1.173531,"marketCap":300210089},{"date":"2024-09-13","current":-1.496275,"twenty":-2.390626,"median":-1.497092,"eighty":-1.177113,"marketCap":343616533},{"date":"2024-09-20","current":-1.540036,"twenty":-2.248325,"median":-1.497406,"eighty":-1.182548,"marketCap":353666301},{"date":"2024-09-27","current":-1.616387,"twenty":-2.173184,"median":-1.49772,"eighty":-1.183457,"marketCap":371199939},{"date":"2024-10-04","current":-2.374287,"twenty":-2.173184,"median":-1.519153,"eighty":-1.187433,"marketCap":545250240},{"date":"2024-10-11","current":-2.176603,"twenty":-2.352646,"median":-1.530726,"eighty":-1.193387,"marketCap":499852543},{"date":"2024-10-18","current":-2.257757,"twenty":-2.310612,"median":-1.544226,"eighty":-1.200277,"marketCap":518489492},{"date":"2024-10-25","current":-2.299664,"twenty":-2.339564,"median":-1.569114,"eighty":-1.208188,"marketCap":528113202},{"date":"2024-10-31","current":-2.199769,"twenty":-2.325678,"median":-1.616387,"eighty":-1.208566,"marketCap":505172538},{"date":"2024-11-08","current":-2.028231,"twenty":-2.320475,"median":-1.625846,"eighty":-1.217877,"marketCap":496569789},{"date":"2024-11-15","current":-1.766791,"twenty":-2.31186,"median":-1.676743,"eighty":-1.221601,"marketCap":432561563},{"date":"2024-11-22","current":-1.725268,"twenty":-2.307988,"median":-1.693927,"eighty":-1.221601,"marketCap":422395604},{"date":"2024-11-29","current":-1.954681,"twenty":-2.306323,"median":-1.709478,"eighty":-1.229672,"marketCap":478562529},{"date":"2024-12-06","current":-2.388593,"twenty":-2.306323,"median":-1.725268,"eighty":-1.23169,"marketCap":584796802},{"date":"2024-12-13","current":-2.088591,"twenty":-2.321516,"median":-1.757967,"eighty":-1.238401,"marketCap":511347747},{"date":"2024-12-20","current":-2.024787,"twenty":-2.313583,"median":-1.76875,"eighty":-1.241197,"marketCap":495726646},{"date":"2024-12-27","current":-2.088883,"twenty":-2.309537,"median":-1.777713,"eighty":-1.243092,"marketCap":511419083},{"date":"2025-01-03","current":-1.778913,"twenty":-2.307156,"median":-1.777862,"eighty":-1.244452,"marketCap":435529430},{"date":"2025-01-10","current":-1.777862,"twenty":-2.305849,"median":-1.777862,"eighty":-1.244878,"marketCap":435272177},{"date":"2025-01-17","current":-1.989062,"twenty":-2.304427,"median":-1.779554,"eighty":-1.246554,"marketCap":486980042},{"date":"2025-01-24","current":-2.040548,"twenty":-2.299664,"median":-1.784789,"eighty":-1.253258,"marketCap":499585442},{"date":"2025-01-31","current":-2.036345,"twenty":-2.283748,"median":-1.80308,"eighty":-1.272811,"marketCap":498556430},{"date":"2025-02-07","current":-1.976453,"twenty":-2.276485,"median":-1.8278,"eighty":-1.28026,"marketCap":483893005},{"date":"2025-02-14","current":-1.999569,"twenty":-2.273364,"median":-1.845442,"eighty":-1.299813,"marketCap":489552573},{"date":"2025-02-21","current":-2.060513,"twenty":-2.263946,"median":-1.859179,"eighty":-1.303538,"marketCap":504473250},{"date":"2025-02-28","current":-1.892393,"twenty":-2.258524,"median":-1.87682,"eighty":-1.306703,"marketCap":463312761},{"date":"2025-03-07","current":-1.875581,"twenty":-2.211367,"median":-1.875581,"eighty":-1.307262,"marketCap":459196712},{"date":"2025-03-14","current":-5.557927,"twenty":-2.211367,"median":-1.881886,"eighty":-1.317995,"marketCap":430316947},{"date":"2025-03-21","current":-5.33039,"twenty":-2.277938,"median":-1.88594,"eighty":-1.323353,"marketCap":412700118},{"date":"2025-03-28","current":-4.805047,"twenty":-2.306323,"median":-1.893969,"eighty":-1.325512,"marketCap":372025970},{"date":"2025-04-04","current":-4.129128,"twenty":-2.32984,"median":-1.905491,"eighty":-1.337057,"marketCap":319693626},{"date":"2025-04-11","current":-3.466594,"twenty":-2.375387,"median":-1.926854,"eighty":-1.34432,"marketCap":268397566},{"date":"2025-04-17","current":-3.536863,"twenty":-2.423443,"median":-1.931271,"eighty":-1.357169,"marketCap":273838057},{"date":"2025-04-25","current":-4.03209,"twenty":-2.511189,"median":-1.940728,"eighty":-1.376163,"marketCap":312180567},{"date":"2025-05-02","current":-4.105705,"twenty":-2.552358,"median":-1.945456,"eighty":-1.384171,"marketCap":317880129},{"date":"2025-05-09","current":-7.05935,"twenty":-3.360856,"median":-1.954681,"eighty":-1.385102,"marketCap":270443712},{"date":"2025-05-16","current":-7.066125,"twenty":-3.485332,"median":-1.967259,"eighty":-1.38715,"marketCap":270703255},{"date":"2025-05-23","current":-6.195562,"twenty":-3.649293,"median":-1.975402,"eighty":-1.394326,"marketCap":237351991},{"date":"2025-05-30","current":-6.774808,"twenty":-3.931706,"median":-1.977504,"eighty":-1.416672,"marketCap":259542910},{"date":"2025-06-06","current":-6.327671,"twenty":-4.025398,"median":-1.983808,"eighty":-1.446219,"marketCap":242413077},{"date":"2025-06-13","current":-6.937404,"twenty":-4.149205,"median":-1.989062,"eighty":-1.451731,"marketCap":265771939},{"date":"2025-06-20","current":-6.774808,"twenty":-4.316511,"median":-1.991374,"eighty":-1.456219,"marketCap":259542910},{"date":"2025-06-27","current":-7.76393,"twenty":-4.826462,"median":-1.999044,"eighty":-1.463428,"marketCap":297436174},{"date":"2025-07-03","current":-7.59456,"twenty":-4.979046,"median":-2.003247,"eighty":-1.47767,"marketCap":290947602}],"updateTime":1751686574406}}}